Lexicon Pharmaceuticals, Inc. (LXRX) Stock Analysis & Investment Frameworks
Lexicon Pharmaceuticals, Inc. (LXRX) stock analysis on Invetso. Review Lexicon Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Lexicon Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Lexicon Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $792.02M
- Revenue: $49.80M
- ROE: -37.80%
- ROIC: -26.86%
- Dividend Yield: N/A
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.